Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lebrikizumab Phase 2b in Moderate-to-Severe Atopic Dermatitis
NCT03443024Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2018
- Primary completion
- Feb 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of lebrikizumab in atopic dermatitis (AD), sponsored by Eli Lilly and Company. Started Jan 2018; status: completed.
02
Drugs
lebrikizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03443024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03443024.